Business Description
Adaptimmune Therapeutics PLC
ISIN : US00653A1079
Share Class Description:
STU:473A: ADRDescription
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its product pipelines include ADP-600 [PRAME] and ADP-520 [CD70].
Financial Strength
| Name | Current | Vs Industry | Vs History |
|---|
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
9-Day RSI | 46.6 | |||||
14-Day RSI | 48.3 | |||||
6-1 Month Momentum % | -47.37 | |||||
12-1 Month Momentum % | -80.2 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History |
|---|
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Adaptimmune Therapeutics PLC Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 58.526 | ||
| EPS (TTM) (€) | -0.623 | ||
| Beta | 0.4686 | ||
| 3-Year Sharpe Ratio | -0.49 | ||
| 3-Year Sortino Ratio | -0.7 | ||
| Volatility % | 158.07 | ||
| 14-Day RSI | 48.3 | ||
| 14-Day ATR (€) | 0.000029 | ||
| 20-Day SMA (€) | 0.01 | ||
| 12-1 Month Momentum % | -80.2 | ||
| 52-Week Range (€) | 0.001 - 0.232 | ||
| Shares Outstanding (Mil) | 265.05 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 0 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Adaptimmune Therapeutics PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Adaptimmune Therapeutics PLC Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-20 08:00 | In 179 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-20 | In 178 days | ||
| Third quarter earnings results for 2026 | 2026-11-13 | In 79 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-13 | In 79 days | ||
| Second quarter earnings results for 2026 | 2026-08-27 | In 1 day | ||
| General meeting for 2026 | 2026-06-29 06:00 | 0.01 (+0.00%) | ||
| Annual report for 2025 | 2026-05-20 | 0.01 (-41.18%) | ||
| Second quarter earnings results for 2025 | 2025-08-13 | 0.07 (+0.00%) | ||
| General meeting for 2025 | 2025-05-29 10:00 | 0.24 (-0.84%) | ||
| First quarter earnings conference call for 2025 | 2025-05-13 08:00 | 0.26 (+2.36%) |
Show
Entries
Adaptimmune Therapeutics PLC Frequently Asked Questions
What is Adaptimmune Therapeutics PLC(STU:473A)'s stock price today?
The current price of STU:473A is €0.01. The 52 week high of STU:473A is €0.23 and 52 week low is €0.00.
When is next earnings date of Adaptimmune Therapeutics PLC(STU:473A)?
The next earnings date of Adaptimmune Therapeutics PLC(STU:473A) is 2026-08-27 Est..
Does Adaptimmune Therapeutics PLC(STU:473A) pay dividends? If so, how much?
Adaptimmune Therapeutics PLC(STU:473A) does not pay dividend.
Press Release
Articles on Adaptimmune Therapeutics PLC
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers